This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk04: and I will be a conference operator today. At this time, I would like to welcome everyone to the live stand held first quarter 2024 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speakers remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. I would now like to turn the call over to Monica Prokoski, vice president of investor relations. Please go ahead.
spk07: Thank you, operator. Good morning, everyone, and welcome to LifeStand Health first quarter 2024 earnings conference call. I'm Monica Prokoski, vice president of investor relations. Joining me today are Ken Burdick, chief executive officer, Dave Borden, chief financial officer, and Donnish Koreshi, chief operating officer. We issued the earnings release and presentation before the market opened this morning. Those are available on the investor relations section of our website, .lifestands.com. In addition, a replay of this conference call will be available following the call. Before turning the call over to management for their prepared remarks, please direct your attention to the disclaimers about forward-looking statements included in the earnings press release and SEC filings. Today's remarks contain forward-looking statements, including statements about our financial performance outlook, business model, and strategy. Those statements involve risks, uncertainties, and other factors, as noted in our periodic filings with the SEC, that could cause actual results to differ materially. In addition, please note that we report results using non-GAAP financial measures, which we believe provide additional information for investors to help facilitate comparison of current and past performance. A reconciliation to the most directly comparable GAAP measures is included in the earnings press release table and presentation appendix. Unless otherwise noted, all results are compared to the comparable period in the prior year. At this time, I'll turn the call over to Ken Burdick, CEO of Lifestance.
spk13: Ken? Thanks, Monica, and thank you all for joining us today. In the first quarter, we once again beat on all our guided metrics, making this the sixth consecutive quarter that Lifestance has met or exceeded expectations. We delivered strong financial performance with revenue growth of 19% to $300 million and adjusted EBITDA up 174% to $28 million. We are also raising full-year adjusted EBITDA guidance based on the strength of the quarter. Our clinician value proposition continues to resonate with 221 net clinician ads in the quarter, representing 15% entirely organic growth in our clinician base. Our patient experience continues to receive outstanding scores, with a patient net promoter score of 84 and average Google reviews across Lifestance centers at 4.5 out of 5 stars. Before covering our strategic and operational highlights, I would like to share the news that Donnish has reached the difficult decision to leave Lifestance. Knowing this was not an easy decision, I'd like to give Donnish the opportunity to directly share his thoughts with all of you.
spk11: Thank you, Ken.
spk12: In
spk11: March,
spk12: we celebrated the seven-year anniversary of the founding of Lifestance. That's given me the chance to reflect on all that we have achieved over the years in service of our mission of increasing access to affordable mental health care. As one of the founders of Lifestance, it's been a remarkable journey as we've grown the company from our first practice group of approximately 100 clinicians in Ohio to almost 7,000 clinicians across 33 states, touching the lives of millions of patients for the better all along the way. It's been one of the great joys of my life to have contributed to those achievements. Two years ago, it became clear that we needed to make the shift from a high-growth startup to a scale public company. At that time, I stepped into the role of President and COO with a goal of solidifying the foundation of the business, rebuilding and up-skilling our operations leadership team, and moving us to a performance-driven organization. I am so proud of all that we've accomplished since then, and I'm particularly proud of the shift and strength of the operations leadership team we've built. No better demonstrated than by our delivering six sequential quarters of meeting and exceeding our financial commitments. Having enjoyed the privilege of building Lifestance since its founding, and having spent the last two years turning Lifestance into a high-performing and stable public company, for me, now is the right time to step away and take on my next challenge. As an entrepreneur and builder at heart, I have the desire and drive to make a similar impact on other parts of the healthcare ecosystem, as I have had the privilege of doing so here at Lifestance. This has not been an easy decision, and I want to thank all of those who have helped me as I thought this through over the previous month. I will continue to operate in my current role through the end of June, however, many of the changes needed to ensure a smooth transition have been put into place over the course of the last two years as we have built out our leadership bench strength and worked together to solidify our foundation. While I'm excited about my next chapter, I have never felt more confident in the future of Lifestance, and I look forward to seeing all that the team achieves over the coming years. With that, I'll pass it back to Ken.
spk13: Thank you, Donnish. I have appreciated Donnish's contributions and have enjoyed the partnership that we've developed. He has made an extraordinary impact on the organization over the past seven years. I am grateful that he has engaged in these conversations with myself and the board to ensure a smooth transition through his final day. I know that I speak for the entire leadership team when I express profound appreciation for his contribution to Lifestance and a genuine desire for his continued success in the next chapter of his career. As Donnish referenced, Lifestance is well positioned to continue our exciting journey of expanding access to high quality, affordable mental health care. We have made strong progress on improving our operations and strengthening our team. To ensure a smooth transition, several of our leaders have already stepped into increased responsibility for which they are well prepared and most deserving. My conviction is stronger than ever regarding the ability of Lifestance's unique business model to address the challenges that have long existed within the industry. We see the benefits of our model play out through an exceptional patient experience, continued clinician growth, and our ability to navigate industry challenges in ways that positively differentiate us from other mental health companies. The recent cyber attack on change healthcare offers a tangible proof point
spk11: of
spk13: Lifestance's differentiation and resilience. While change healthcare systems were down, many mental health provider groups experienced unprecedented financial distress due to their inability to process claims and receive reimbursement, which in many cases affected their ability to pay their clinicians for the services they provided. Our clinicians are W-2 employed and paid on a -for-service basis with guaranteed rate schedules. Thanks to our scale and flexibility, we have been able to absorb 100% of the impact of reimbursement delays without financial disruption to our clinicians. Additionally, we have been able to achieve this without the need to raise debt or equity capital, and as Dave will touch on shortly, we remain on track to be free cash flow positive for the full year of 2024. Shifting to payer strategy, we have previously stated that we are becoming more assertive in demanding appropriate reimbursement and terms for our services. Overall, we've been successful in these efforts as evidenced by the 4% -over-year increase we saw in total revenue per visit in the first quarter. This was driven by the positive outcomes of several contract negotiations in late 2023 and early 2024. Our increased engagement has translated into improved reimbursement from payers. However, we had a single outlier with historically above-market rates for negotiated reimbursement that will now bring them in line with our overall book of business. This will create short-term downward pressure on total revenue per visit for the back half of 2024 and the first part of 2025. Importantly, this both de-risks our overall portfolio and has already been contemplated in our 2024 guidance rates. This is another demonstration of our resilience and ability to deliver on our commitments. We continue to expect total revenue per visit to increase by low single digits for the year, and in the medium and longer term, we continue to see meaningful upside opportunity to increase the level of reimbursement with payers. With our unique outpatient and in-network business model, we provide both patients
spk11: and
spk13: our payer partners with an affordable option for increasing access to much needed mental healthcare services. Before closing, I am pleased to announce that we welcomed Dr. Teresa DeLuca to our board of directors. She is a psychiatrist and accomplished physician executive with over 20 years of leadership experience in healthcare operations and clinical management. I am confident that Teresa will be a great addition to the Lifespan's board. With that, I'll turn it over to Dave to provide additional commentary on our financial performance and outlook. Dave? Hey, thanks, Ken.
spk02: Like Ken, I'm pleased with the team's operational and financial performance in the first quarter. We delivered solid top-line results with revenue of $300 million, representing growth of 19% year over year. The outperformance was primarily driven by higher total revenue per visit and increased visit volumes. Both were modestly above our expectations. Visit volumes of 1.9 million increased 15% year over year, primarily driven by higher organic clinician growth. In the first quarter, we added 221 net clinicians, which was above our expectations. This brings our total clinician base to 6,866 clinicians, representing growth of 15% year over year. While we do not guide on clinician count, I wanna highlight that we expect net clinician ads in the second quarter to be meaningfully lower than the first quarter, which is similar to the dynamic we saw last year with the trend reversing later in the year. Clinician productivity was in line with our expectations in the first quarter, with the timing of holidays and spring breaks impacting clinician capacity. Total revenue per visit increased by 4% year over year to $157, primarily driven by payer rate increases. Regarding profitability, the better than expected top-line results flowed through to center margin. Center margin of $95 million in the quarter increased by 36% year over year, and center margin as a percentage of revenue grew nearly four points to 31.5%.
spk11: The year over year improvement was primarily due to higher total revenue per visit and operating leverage in center margin of $157 million per year.
spk02: Outperformance in the quarter was driven by favorable spending and to a lesser extent, higher total revenue per visit. Adjusted EBITDA of $28 million in the quarter was very strong and outperformed our expectations, increasing 174% year over year. Outperformance in the quarter was driven by favorable spending and adjusted EBITDA as a percentage of revenue grew over five points to 9.2%. The outperformance in adjusted EBITDA is attributable to the improvement in center margin. Turning to liquidity. In the first quarter, free cash flow was negative $27 million. We exited the quarter with $49 million in cash and net long-term debt of $280 million. As Ken touched on, we did see a temporary disruption to our cash collections from the cyber attack on change healthcare. This resulted in a net impact of approximately $18 million comprised of delayed cash collections partially offset by stronger cash management. DSO increased to 53 days in the quarter with the impact from change being approximately nine days. The impact from change is expected to be a timing issue that will largely resolve itself in the second quarter. We are already seeing progress with improved DSO in April and anticipate that DSO will revert back to normal later this year. As a result of this, we remain confident in our commitment to deliver positive free cash flow in 2024. We also have additional debt capacity from a delayed draw term loan of $8 million, as well as a $50 million revolving debt facility providing us with sufficient financial flexibility and have no intention of raising additional debt or equity. We continue to see improvement in our leverage ratios with net leverage improving sequentially over 40 basis points to 3.1 times. We remain confident that we will finish the year with net leverage below two and a half times.
spk11: In terms of our outlook for
spk02: 2024, we are maintaining our full year revenue range of ,000,000 to ,000,000. We feel good about the improved margin performance of the business and are raising the center margin range by $8 million at the midpoint to $353 to $373 million, and the adjusted even a range by $8 million at the midpoint to $88 to $98 million. We continue to expect the earnings to have a different quarterly progression compared to 2023, which was more weighted to the back half. Whereas this year, we will be more weighted to the front half of the year. As Ken noted, we will see a negative impact on total revenue per visit in the second half as a result of a rate decrease from one payer, partially offset by increases from others. We continue to expect total revenue per visit to increase by low single digits for the year. In the medium and longer term, we continue to see meaningful upside opportunity to increase the level of reimbursement with payers and remain confident in our commitment to exit 2025 at double digit margins. For the second quarter, we expect revenue of 297 to $315 million, center margin of 85 to $97 million, and adjusted even a of 20 to $26 million. With that, I'll turn it back to Ken for his closing remarks.
spk13: Thank you, Dave. In closing, I'm proud of the results achieved by our clinicians and team members this quarter. We delivered strong organic revenue growth while executing on our commitment to deliver -over-year operating leverage and margin expansion. I'd like to once again thank Donnish for his contributions to Lifestance and wish him well on his career journey.
spk11: While we are sad to see him go, we are well positioned to continue delivering on our mission of expanding access to
spk13: high quality, affordable mental health care. Quality, quality, affordable mental health care. While I recognize that we still have a great deal of work ahead in 2024 and beyond, I am encouraged by the momentum we are building toward our stated commitments of positive free cash flow in 2024, growing revenue at mid-teens through 2025, and exiting 2025
spk11: with double-digit margins. As a country, we have underfunded mental health care and
spk13: underserved millions of individuals for far too long. Our team at Lifestance will continue to work tirelessly to address these challenges
spk11: until mental health parity is a reality. Operator, we're now ready for questions.
spk04: Thank you. We will now begin the question and answer session. If you have dialed in and would like to ask a question, please press star one on your telephone keypad to raise your hand and join the queue. If you would like to withdraw your question, simply press star one again. If you are called upon to ask your question and are listening via loudspeaker on your device, please pick up your handset and ensure that your phone is not on mute when asking your question. Again, press star one to join the queue, and your first question comes from the line of, Craig, head and back with Morgan Stanley. Please go ahead.
spk09: Yes, thank you. I wanted to touch on the better than expected center margin EBITDA. Ken, when you joined, there was a focus and increased emphasis on kind of building a foundation, increased investments in the business, and it looks like that's starting to translate. So we'd love to get your take and just operating leverage in the model as you see it and kind of how you see that path to 10% margins exiting next year.
spk13: Sure, thanks for the question, Craig. You're right. I think we are encouraged by the operating leverage that we're beginning to experience. I would also highlight that we had some delayed expense that contributed to an outperformance, and also that, as I've shared before, this is sort of a two-year journey of rebuilding and strengthening the foundation, improving the processes. So I would view this as initial progress and some demonstration of the benefit, but my view is we're sort of five quarters into what's likely gonna be an eight or nine quarter improvement in our operating efficiency and therefore operating leverage.
spk09: Got it, and then just as a follow-up, I wanted to touch on just capacity and just any update. There's efforts to improve capacity by moving clinicians more towards full-time arrangements, so kind of where things stand there and what that could mean over the next 12 to 18 months.
spk12: Yeah, hey, Craig, this is Donish. I can answer that. So like we discussed on last quarter's earnings call, because of all the work that we put into on the utilization side of the productivity equation, we have begun our shift towards the capacity side. A lot of those plans have just started to get underway in Q1, so it's early days, and we're hoping that that will start to play out in a more meaningful way throughout the course of the year, but as a reminder, we have not, in our guidance, included any assumptions around improvements in productivity. So again, early days are on capacity, and we'll continue to provide updates as they make sense.
spk11: Thank you.
spk03: For everyone who's here, we do request
spk04: for today's session that you please limit to one question and one follow-up. Your next question comes from the line of Lisa Gill with JPMorgan. Please go ahead.
spk01: Thanks very much, good morning. First off, Donish, I want to say I wish you the best in your next endeavor. It was nice getting to know you. For my question, Ken, I want to understand when we think about the payer strategy, you talked about the single outlier that's now in line. Can you maybe just talk about, was that a really unusual contract that was signed? I just want to better understand why it was an outlier, and then secondly, when we think about the new contracts that are being signed, is there anything that's changing in the contracting? I agree with you how important mental health is and the lack of mental health providers we have, so I was just a little surprised to hear that there is this one outlier. I just want to better understand that. Thanks so much.
spk13: Sure, thanks for the question. It really was, it was a historic outlier and meaningfully higher than sort of the portfolio of contracts that we had, and it goes back several years. We would have loved for it to continue, but we always knew that there was a possibility that through negotiations, it would come back to sort of where the overall market is for us. So it truly was unique, and we are being paid, as I say, consistent with the rest of our payer community. We will continue to look for upgrades because it's not identical. One of the things that we feel is that everyone should pay their fair share, and so we continue to work on that. As it relates to sort of the demand supply, what's really important to remember is that employers are really demanding better access for their employees and their employees' dependents, and because of that fact, we have constructive discussions and negotiations with payers, and while I would love to see us move into more value-based contracting, I would say right now we're in the very, very early stages of that, and you'll see and hear more about that in the years to come, but there's really no major change other than the drumbeat from employers
spk11: for greater access.
spk03: Great, thank you. Next question comes from the line of Ryan Daniels
spk04: with William Blair. Please go ahead.
spk08: Hey guys, this is Jack Stumpston for Ryan Daniels. Thanks for taking the question, and congrats on the quarter. I just wanna go back to basically the same line of questions. For the payer outlier that had the above market rate, can you just talk just a little bit more about it? I'm assuming that this is a payer that had significant volume given the near-term impact, so is there any way to kind of quantify the impact, or I guess how we should think about the impact? I understand the downward pressure, but just curious if you can dive a little bit deeper into that, thanks.
spk13: Yeah, we're gonna resist the temptation to get very specific about any one single payer negotiation. As you can appreciate, whether it's in this case going down or in many and most other cases going up, it doesn't behoove us to get into the specific details of any one single negotiation. So I can confirm that yes, it's a national payer with significant volume, which is why we thought it was important in this call to share that while we had an outstanding first quarter, we wanna be sure people, as they do their modeling, don't just extrapolate from the first quarter, multiply it by four and say, okay, you're on your way to an unbelievable beat. We had a great beat in the first quarter, and what we're trying to project in both our prepared remarks and during the Q&A is we expect that the rest of the year will play out in consistent with our original commitments and the budget that we have committed to. Okay,
spk08: understood, thanks for the call. And just a quick follow up too, I think it was an answer to a previous question, but you mentioned a delayed expense that led to an outperformance this quarter. So can you just talk a little bit more about this as well? I mean, maybe I missed it in the prepared remarks, but what exactly was that and maybe how much, and then to like, will this be delayed then to kind of feeding into the second quarter kind of how we should think about that, thanks.
spk02: Hey, good morning, Jack, it's Dave, I'll take that one. So the beat in the first quarter primarily came through performance in center margin, and it was spent within that center margin bucket. And a lot of that was, it's delayed in the sense of we expected it to happen in the first quarter, and a lot of it is pushing into the second quarter. And it's things like the investment, we're making in the digital patient check-in tool, as well as investments that we're making in the front office of our centers, we've talked about in our last earnings call. So those were all investments that we were planning on making throughout the year. They're just getting off the ramp a little bit slower than we thought, and that's what primarily contributed to the Q1 beat and why that's not
spk11: flowing through to the remaining quarters. Thank you. All right, your next question
spk03: comes from the line of Kevin Kaliendo
spk04: with UBS, please go ahead.
spk10: Thank you, thanks for taking my question. Donnish, congrats on all your achievements at LifeStance and best of luck going forward. It was a pleasure getting to know you. I just want to go back to the payer stuff again. I just want to understand that a little bit better. Does the new sort of rates kick in on July 1? Is that why the cadence in the second half is not as great or not the normal seasonality? And two, maybe just to provide a little bit of comfort around this more, how often are these payer rates negotiated? And can you talk about any negotiations that would have started one-one on a same-store basis? Like typically, what do you normally see when you redo or renew a payer relationship?
spk13: Yeah, it's not quite as structured and organized as January 1 of every year we renegotiate. All of our contracts. This is really as we engage in a much more wholesome, comprehensive fashion, we're talking about rates, we're talking about sort of the terms, we're talking about delegated credentialing, etc. So these are pretty comprehensive discussions. Historically, it's been sort of a non-event that maybe there was a 1% add-on for future years and we've changed that. So now we're having these deeper, more strategic discussions about what the relationship is going to look like. And in some cases, there are multi-year contracts and in others, they are annual, but they happen throughout the year. And so I would describe it as lumpy. Even this particular contract renegotiation, there's different lines of business that come into effect at different times. So I can't even tell you that everything happens on July 1. There's sort of a phase-in and it's a little bit more nuanced than just sort of one single change in rate on one given date. And maybe just to pile on
spk02: to Ken's comments, from a modeling perspective, if you're thinking about TRPV, what you're saying is generally accurate, which is we would expect TRPV in the first half of the year to be higher than the back half of the year. So to answer that specific
spk11: question. Okay. Thank you.
spk03: Next question comes from the line of Brian Tanquile with Jefferies.
spk04: Please
spk06: go ahead. Thank you for taking my question. You have Taji Phillips on for Brian. So first, Donish, I want to say congratulations to you. It was wonderful working with you. And so my first question is going to be on clinician ads in the quarter. I know that you guys had mentioned that they had exceeded your expectations. So maybe you can just provide an update on several different KPIs, retention, recruitment, turnover, right within your clinician base. And then I have a follow-up from there.
spk12: Hey, Taji, this is Donish. Thanks for the comment. And I can address the question around next clinician ads and some of the drivers. So yes, we're very pleased with our next clinician ads in Q1 that exceeded our expectations. Again, that was 100% organic, which is something that we remain very proud of. Retention continues to remain stable. Our recruiting engine continues to be what we characterize as best in class. Our value proposition to our clinicians, both those that are here as well as new ones that we're trying to attract, continues to remain strong. And so we feel good about our ability to continue to deliver strong next clinician ads throughout the year. Dave did mention in the prepared remarks, the dynamic that we see around Q2, where you typically see a lower number that reverses later in the year just due to seasonality and the fact that because we are delivering this on a 100% organic basis now, the seasonality is more visible than in previous years where we had M&A as a component on top of organic. So hopefully that provides some additional color on what we're seeing there.
spk06: And that was great. Thank you, Donnish. And then another follow-up there. I know this is more recent news and obviously still preliminary and there's been some pushback on this, but thinking about the FTC's potential non-compete ban, how are you thinking about the impact to your business and just the general recruiting environment for clinicians in behavioral health space?
spk12: Yeah, I can take that as well. So for us, we do in states that at least today allow for non-competes have that in our contracts, but not all states even today allow for it and in those states we do not. Though we have included that in contracts, we have never built the value proposition around non-competes. For us, it's about what are we providing to our clinicians to both not just attract but retain them and making sure that we're constantly solidifying and bolstering that value proposition. So for us, this is not something where it's a particular worry. If anything, we'd be hopeful that it creates more movement on the recruiting side in our ability to attract clinicians from other practice groups where they currently may feel restricted to explore other opportunities.
spk03: Thank you. Your next question comes from the line of Stephanie Davis with Barclays. Please go ahead.
spk05: Hey guys, congrats on the quarter and congratulations on the accomplishments today. Best of luck in the next week. I want to ask a little bit about the CLO transition. Is there any sort of succession plan? Is this the role you're expecting to keep? And then I guess the follow-up related to that would be, is there a read-through considering there's been a bit of a turnaround in the back end in the past year that maybe a lot of this
spk03: is already accomplished?
spk11: I'll speak to the
spk13: first part. You might have to elaborate on the second part. I wasn't sure about the second half of the year comment. But one of the things that Donnish has done so well over the past couple of years is recruit great talent to the organization. And so I do not have an immediate plan to replace Donnish. As he mentioned in his prepared remarks, we've already elevated our leader of shared services and our leader of practice ops to the executive team. And my initial thinking is that they are ready to step up and the rest of us on the ELT will step up. So at this juncture, I'm not in a position to communicate that we're going to do an external search or we're going to promote somebody from within to replace Donnish in kind. And I think it really is a tribute to the strength of the team that we've all built over the last couple of years. We're in a dramatically different place. And one of the things that encourages me that I didn't say in my prepared remarks, I think whether we're talking about change healthcare, we're talking about the departure of a founder, this hard work, which I've told you before, is not sexy and it doesn't show up immediately. It's created a resilience, a stability, and a predictability that we simply didn't have a couple of years ago. And so while I know we will have other surprises thrown at us from time to time, I continue to gain more and more conviction that we are more than prepared to navigate through it.
spk05: And a clear fact... Do you want to elaborate
spk13: on the second part of your question?
spk05: Exactly. It's just I think about how much back-end turnaround has been going on and how that's probably often in the COOs purview. So is the read-through that a lot of the groundwork has already been laid for the back-end operations update and that there's less going forward? Or is it more to say that there's a lot of talent that can handle it in the laboratory?
spk13: Yeah, well, thank you. Now I get it. And I'm happy to speak to that. There is a lot of talent, but one of the things that we have done, and I would say Donnish leading the way, we've created a great deal of clarity around expectations and KPIs and building a culture of accountability. So both the processes and the culture are very different now than they were a couple of years ago. That's part of what I consider Donnish's legacy as a COO. And so I'm just so appreciative that he hung in. Many founders would depart when the company went public. And this will be Donnish's second very successful startup. So I look at this as thank goodness he hung with us for a couple of years because the work that he did as he transitioned from head of business development and chief growth officer to COO has been incredibly powerful and sets us up for success. To your point, while there's still way more work to be done, we have made a major pivot. And I think I won't speak for Donnish, but based on all of our -on-one conversations, it is a big part of the reason why he feels like now
spk11: is the right time.
spk03: Helpful. Thank you. That concludes our Q&A session. I
spk04: will now turn the conference back over to Ken Burdick, chief executive officer, for closing remarks.
spk13: Thank you, operator. I want to thank everybody for participating on today's call. I want to also thank our approximately 9,500 employees who have such a deep sense of purpose and commitment to what we are doing, which is trying to increase access to high-quality, affordable mental health care. And you've heard me say multiple times that this is an underserved population. And I just want to put a couple of statistics around that. Mental health clinicians currently are reimbursed 22% less than their counterparts on the med-surg side of the business. And patients go out of network three and a half times more often. So in addition to the struggles that folks have even developing and coming up with the courage to seek care, there is a financial burden when they have to go out of network and incur those -of-pocket costs, which I just don't think is the country that we want to live in. So we have tens of millions of individuals across this country who do not have access to services that they need. And as I said in my closing, I couldn't be more proud and more committed to the mission of LifeStance, which is to address that. And because of our size and scale, we think we can have a meaningful impact on the trajectory for years to come. So I want to thank all of our employees, and I want to thank all of you for your interest in
spk11: LifeStance.
spk03: Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.
Disclaimer